Celecoxib suppresses cutaneous squamous-cell carcinoma cell migration via inhibition of SDF1-induced endocytosis of CXCR4
Authors Gong T, Yu Y, Yang B, Lin M, Huang JW, Cheng B, Ji C
Received 17 July 2018
Accepted for publication 15 October 2018
Published 12 November 2018 Volume 2018:11 Pages 8063—8071
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Prof. Dr. Geoffrey Pietersz
Ting Gong,1,* Yan Yu,2,* Bo Yang,3 Min Lin,4 Jin-Wen Huang,4 Bo Cheng,4 Chao Ji4
1Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, China; 2Department of Dermatology, First Hospital of Jilin University, Changchun, Jilin 130021, China; 3Department of Dermatology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China; 4Department of Dermatology, First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian 350005, China
*These authors contributed equally to this work
Background: Cutaneous squamous cell carcinoma (CSCC), the main type of non-melanoma skin cancer (NMSC), contributes to 20-30% of the overall number of NMSC cases. Some CSCCs are observed to have metastatic potential induced by solar ultra violet (UV) radiation. Celecoxib, a nonsteroidal anti-inflammatory drug, has been largely associated with prevention of many cancer types. However, the relationship between celecoxib and CSCC cell migration has yet to be determined.
Methods: To determine the association between celecoxib and CSCC, we performed a series of studies in human samples and in vitro models to assess the influence of celecoxib in CSCC cell migration.
Results: In the present study, we found that celecoxib suppresses CSCC cell migration via inhibition of SDF1-induced endocytosis of CXCR4. In addition, ERK/AKT signaling pathways were found to play a key role in this biological process.
Conclusion: Our study provides promising evidence that celecoxib could serve as a potential preventative agent for the metastasis of CSCC cells.
Keywords: celecoxib, SDF1, cell migration, CXCR4, ERK–Akt pathway
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]